CEL-SCI Signs Strategic Partnership Agreement with Amarox
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 11 2026
0mins
CEL-SCI announced it has signed a strategic partnership, distribution, and revenue sharing agreement with Amarox for regulatory affairs, marketing and potential commercialization of Multikine in the treatment of head and neck cancer in Saudi Arabia, with an optional extension for the Gulf Cooperation Council countries including Bahrain, Kuwait, Oman, Qatar, and the United Arab Emirates. Amarox will support and coordinate the local regulatory process with SFDA, including seeking the SFDA's Breakthrough Medicine Designation which, upon granting, would make Multikine rapidly available to patients in Saudia Arabia, representing a pivotal shift in CEL-SCI's commercial trajectory. The companies will share net revenue from sales of Multikine in Saudi Arabia on a 50%/50% basis. Upon SFDA approval, Amarox will receive exclusive rights to distribute Multikine for the treatment of head and neck cancer in Saudi Arabia. CEL-SCI retains full ownership of all Multikine intellectual property, manufacturing know-how and global rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVM
About CVM
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cel-Sci Releases Q2 Financial Results
- Financial Performance: Cel-Sci reported a Q2 GAAP EPS of -$1.35, indicating ongoing challenges in profitability and reflecting persistent financial pressure on the company.
- Cash Flow Status: As of the reporting period, Cel-Sci had cash and cash equivalents of $1.89 million, suggesting tight liquidity that may impact future operations and R&D investments.
- Historical Performance Comparison: Compared to the previous quarter, Cel-Sci's GAAP EPS deteriorated from -$0.68 to -$1.35, raising concerns among investors regarding the company's future outlook and financial health.
- Financial Transparency: The financial information provided by Cel-Sci highlights challenges in sustaining operations, prompting investors to closely monitor the company's subsequent financial strategies and market responses.
See More
CEL-SCI Prices Public Offering of 6M Shares at $1.20 Each
- Offering Details: CEL-SCI has priced a public offering of 6 million shares of common stock at $1.20 per share, with total gross proceeds expected to be approximately $7.2 million before deducting placement agent fees and offering expenses, indicating the company's ability to raise capital in the market.
- Use of Proceeds: The funds raised will be allocated for the continued development of Multikine, general corporate purposes, and working capital, highlighting the company's strategic focus on its core product and future growth initiatives.
- Market Reaction: Following the announcement of the public offering, CEL-SCI's stock price declined about 10% during pre-market trading on Tuesday, reflecting market concerns regarding the financing and fluctuations in investor sentiment.
- Financial Performance Overview: CEL-SCI reported a GAAP EPS of -$0.68, indicating ongoing challenges in profitability, which may affect investor confidence in the company's future development.
See More
CEL-SCI Corporation Prices Public Offering
- Public Offering Details: CEL-SCI Corporation has priced a public offering of 6 million shares at $1.20 each, with expected gross proceeds of approximately $7.2 million before deducting placement agent fees and offering expenses, indicating the company's ability to raise capital effectively.
- Use of Proceeds: The funds raised will be allocated for the continued development of Multikine, general corporate purposes, and working capital, reflecting the company's commitment to its cancer immunotherapy and its potential for future growth.
- Underwriter Information: ThinkEquity is acting as the sole placement agent for the offering, managing all aspects of the issuance process, which enhances market confidence and ensures the smooth execution of the offering.
- Regulatory Compliance: The company has filed a registration statement with the SEC, which became effective on May 11, 2026, ensuring that the offering complies with all legal requirements and reducing legal risks for investors.
See More
Cel-Sci Reports Q1 2025 Financial Results with Significant Losses
- Earnings Per Share Loss: Cel-Sci reported a GAAP EPS of -$0.68 for Q1 2025, indicating significant challenges in profitability that could impact investor confidence moving forward.
- R&D Expense Decline: Research and development expenses totaled $3.7 million this quarter, down from $4.4 million in Q4 2024, suggesting the company may be implementing cost-control measures, which could affect future product development timelines.
- Administrative Expense Reduction: General and administrative expenses decreased to $1.7 million in Q1 2025 from $2.5 million in Q4 2024, reflecting improvements in operational efficiency, although the overall financial situation remains precarious.
- Net Loss Overview: The net loss for the quarter was $5.5 million, a reduction from $7.1 million in the prior year period, indicating the company is making efforts to reduce losses while still facing a challenging market environment.
See More
Cel-Sci CEO Buys Shares, Stock Rises 7%
- CEO Share Purchase: Cel-Sci's CEO Geert R. purchased 38,023 shares at $5.26 each on January 22 for approximately $200,000, increasing his total holdings to 120,815 shares, reflecting confidence in the company's future prospects.
- Clinical Trial Preparation: The company is preparing for a confirmatory registration study for its experimental cancer treatment Multikine, aiming to enroll 212 patients with newly diagnosed resectable head and neck cancer, with enrollment expected to begin in spring 2026 and potential approval by 2028 based on generated data.
- Improved Financial Performance: For the fiscal year ending in September, Cel-Sci reported a net loss of $25.4 million, down from $27.6 million in fiscal 2024, indicating efforts to control costs and improve financial health.
- Positive Market Sentiment: On Stocktwits, retail sentiment around CVM stock remained in the 'bullish' territory, with message volume rising from 'high' to 'extremely high', suggesting investor optimism about the company's future developments.
See More
CEL-SCI Files for Breakthrough Designation for Multikine in Saudi Arabia, Plans 212-Patient Enrollment in 2026
- Clinical Trial Progress: CEL-SCI is preparing for a 212-patient Confirmatory Registration Study for newly diagnosed head and neck cancer patients, with enrollment expected to begin in Spring 2026, paving the way for potential early approval in the U.S. and significantly enhancing market competitiveness.
- Survival Rate Improvement: Multikine demonstrated a long-term survival rate of 73% in prior Phase 3 studies compared to 45% in the control group, significantly reducing the risks associated with developing cancer therapies and boosting investor confidence.
- Market Expansion in Saudi Arabia: CEL-SCI has applied for Breakthrough Medicine Designation in Saudi Arabia and is collaborating with a local company to support the Kingdom's Vision 2030, further solidifying its leadership position in the global biotechnology sector.
- Financial Condition Improvement: As of September 30, 2025, CEL-SCI's net loss decreased to $25.4 million, with R&D expenses down 13%, reflecting the company's proactive efforts in cost control and resource optimization.
See More
Cel-Sci Releases Q2 Financial Results
- Financial Performance: Cel-Sci reported a Q2 GAAP EPS of -$1.35, indicating ongoing challenges in profitability and reflecting persistent financial pressure on the company.
- Cash Flow Status: As of the reporting period, Cel-Sci had cash and cash equivalents of $1.89 million, suggesting tight liquidity that may impact future operations and R&D investments.
- Historical Performance Comparison: Compared to the previous quarter, Cel-Sci's GAAP EPS deteriorated from -$0.68 to -$1.35, raising concerns among investors regarding the company's future outlook and financial health.
- Financial Transparency: The financial information provided by Cel-Sci highlights challenges in sustaining operations, prompting investors to closely monitor the company's subsequent financial strategies and market responses.
See More
CEL-SCI Prices Public Offering of 6M Shares at $1.20 Each
- Offering Details: CEL-SCI has priced a public offering of 6 million shares of common stock at $1.20 per share, with total gross proceeds expected to be approximately $7.2 million before deducting placement agent fees and offering expenses, indicating the company's ability to raise capital in the market.
- Use of Proceeds: The funds raised will be allocated for the continued development of Multikine, general corporate purposes, and working capital, highlighting the company's strategic focus on its core product and future growth initiatives.
- Market Reaction: Following the announcement of the public offering, CEL-SCI's stock price declined about 10% during pre-market trading on Tuesday, reflecting market concerns regarding the financing and fluctuations in investor sentiment.
- Financial Performance Overview: CEL-SCI reported a GAAP EPS of -$0.68, indicating ongoing challenges in profitability, which may affect investor confidence in the company's future development.
See More
CEL-SCI Corporation Prices Public Offering
- Public Offering Details: CEL-SCI Corporation has priced a public offering of 6 million shares at $1.20 each, with expected gross proceeds of approximately $7.2 million before deducting placement agent fees and offering expenses, indicating the company's ability to raise capital effectively.
- Use of Proceeds: The funds raised will be allocated for the continued development of Multikine, general corporate purposes, and working capital, reflecting the company's commitment to its cancer immunotherapy and its potential for future growth.
- Underwriter Information: ThinkEquity is acting as the sole placement agent for the offering, managing all aspects of the issuance process, which enhances market confidence and ensures the smooth execution of the offering.
- Regulatory Compliance: The company has filed a registration statement with the SEC, which became effective on May 11, 2026, ensuring that the offering complies with all legal requirements and reducing legal risks for investors.
See More
Cel-Sci Reports Q1 2025 Financial Results with Significant Losses
- Earnings Per Share Loss: Cel-Sci reported a GAAP EPS of -$0.68 for Q1 2025, indicating significant challenges in profitability that could impact investor confidence moving forward.
- R&D Expense Decline: Research and development expenses totaled $3.7 million this quarter, down from $4.4 million in Q4 2024, suggesting the company may be implementing cost-control measures, which could affect future product development timelines.
- Administrative Expense Reduction: General and administrative expenses decreased to $1.7 million in Q1 2025 from $2.5 million in Q4 2024, reflecting improvements in operational efficiency, although the overall financial situation remains precarious.
- Net Loss Overview: The net loss for the quarter was $5.5 million, a reduction from $7.1 million in the prior year period, indicating the company is making efforts to reduce losses while still facing a challenging market environment.
See More
Cel-Sci CEO Buys Shares, Stock Rises 7%
- CEO Share Purchase: Cel-Sci's CEO Geert R. purchased 38,023 shares at $5.26 each on January 22 for approximately $200,000, increasing his total holdings to 120,815 shares, reflecting confidence in the company's future prospects.
- Clinical Trial Preparation: The company is preparing for a confirmatory registration study for its experimental cancer treatment Multikine, aiming to enroll 212 patients with newly diagnosed resectable head and neck cancer, with enrollment expected to begin in spring 2026 and potential approval by 2028 based on generated data.
- Improved Financial Performance: For the fiscal year ending in September, Cel-Sci reported a net loss of $25.4 million, down from $27.6 million in fiscal 2024, indicating efforts to control costs and improve financial health.
- Positive Market Sentiment: On Stocktwits, retail sentiment around CVM stock remained in the 'bullish' territory, with message volume rising from 'high' to 'extremely high', suggesting investor optimism about the company's future developments.
See More
CEL-SCI Files for Breakthrough Designation for Multikine in Saudi Arabia, Plans 212-Patient Enrollment in 2026
- Clinical Trial Progress: CEL-SCI is preparing for a 212-patient Confirmatory Registration Study for newly diagnosed head and neck cancer patients, with enrollment expected to begin in Spring 2026, paving the way for potential early approval in the U.S. and significantly enhancing market competitiveness.
- Survival Rate Improvement: Multikine demonstrated a long-term survival rate of 73% in prior Phase 3 studies compared to 45% in the control group, significantly reducing the risks associated with developing cancer therapies and boosting investor confidence.
- Market Expansion in Saudi Arabia: CEL-SCI has applied for Breakthrough Medicine Designation in Saudi Arabia and is collaborating with a local company to support the Kingdom's Vision 2030, further solidifying its leadership position in the global biotechnology sector.
- Financial Condition Improvement: As of September 30, 2025, CEL-SCI's net loss decreased to $25.4 million, with R&D expenses down 13%, reflecting the company's proactive efforts in cost control and resource optimization.
See More
